Each year approximately 190,000 people in the United States will be diagnosed with a primary or metastatic brain tumor. Brain tumors are the leading cause of solid tumor death in children under age 20 now surpassing acute lymphoblastic leukemia, and are the third leading cause of cancer death in young adults ages 20-39. At present, brain tumors are treated by surgery, radiation therapy and chemotherapy used either individually or in combination. Therapy and clinical outcome for cancers of the central nervous system has not improved significantly in the last three decades. Recent discoveries that provide new insights into the defects in cell signaling that lead to brain tumors are providing an opportunity for the use of molecularly targeted therapeutic drugs. There is an increasing recognition that brain cancer is a disease of molecular pathways that regulate cell growth and division and therefore the field is headed towards customized therapy driven by a rational selection of drug combinations. The key will be to identify which combinations of targeted therapies are most efficacious for each tumor type. Projects 1 and 2 will use a mouse brain tumor model that resembles the human disease with regards to defects in specific signaling pathways, rate of growth as well as histological, immunological and imaging characteristics. The goal of Project 1 is to identify the best non-invasive surrogate MR imaging markers (diffusion, perfusion and proton spectroscopy) for therapeutic efficacy in response to molecularly targeted, traditional, and combination therapies. Successful completion of these aims will significantly impact the design of clinical trials for these novel therapies and combination therapies. Project 2 will investigate the use of noninvasive imaging wherein activation or inhibition of key signaling pathways in cancer can be monitored. These studies will provide unique tools for target validation as well as dose and schedule optimization. Project 1 will also use these tools to validate that the MRI based surrogate marker is faithfully reporting changes in specific signaling pathways in response to targeted agents. These molecularly validated MRI based surrogate markers will then be used in clinical trials of molecularly targeted therapies in Project 3. All three research projects will be supported by four cores, the digital image processing core (Core C), the biostatistics core (Core D) as well as the imaging core (Core B). Overall management of the program project will be accomplished by the administrative core (Core A)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA085878-08
Application #
7799207
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O4))
Program Officer
Menkens, Anne E
Project Start
2000-04-01
Project End
2012-03-31
Budget Start
2010-06-29
Budget End
2011-03-31
Support Year
8
Fiscal Year
2010
Total Cost
$2,367,095
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Galbán, Stefanie; Apfelbaum, April A; Espinoza, Carlos et al. (2017) A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis. Mol Cancer Ther 16:2340-2350
Hu, Xin; Martinez-Ledesma, Emmanuel; Zheng, Siyuan et al. (2017) Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol 19:786-795
Nyati, Shyam; Young, Grant; Ross, Brian Dale et al. (2017) Quantitative and Dynamic Imaging of ATM Kinase Activity. Methods Mol Biol 1596:131-145
Chen, Daiqin; Yang, Dongzhi; Dougherty, Casey A et al. (2017) In Vivo Targeting and Positron Emission Tomography Imaging of Tumor with Intrinsically Radioactive Metal-Organic Frameworks Nanomaterials. ACS Nano 11:4315-4327
Galbán, C J; Hoff, B A; Chenevert, T L et al. (2017) Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed 30:
Martinez, Carlos H; Diaz, Alejandro A; Meldrum, Catherine et al. (2017) Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS. Am J Respir Crit Care Med 195:464-472
Galbán, Stefanie; Al-Holou, Wajd N; Wang, Hanxiao et al. (2017) MRI-Guided Stereotactic Biopsy of Murine GBM for Spatiotemporal Molecular Genomic Assessment. Tomography 3:9-15
Yang, Dongzhi; Comeau, Anthony; Bowen, Wayne D et al. (2017) Design and Investigation of a [18F]-Labeled Benzamide Derivative as a High Affinity Dual Sigma Receptor Subtype Radioligand for Prostate Tumor Imaging. Mol Pharm 14:770-780
Belloli, Elizabeth A; Degtiar, Irina; Wang, Xin et al. (2017) Parametric Response Mapping as an Imaging Biomarker in Lung Transplant Recipients. Am J Respir Crit Care Med 195:942-952
Pompe, Esther; Galbán, Craig J; Ross, Brian D et al. (2017) Parametric response mapping on chest computed tomography associates with clinical and functional parameters in chronic obstructive pulmonary disease. Respir Med 123:48-55

Showing the most recent 10 out of 163 publications